{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:02:24Z","timestamp":1794866544878,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["202305DI1"],"award-info":[{"award-number":["202305DI1"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["152931"],"award-info":[{"award-number":["152931"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["152931"],"award-info":[{"award-number":["152931"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TB Veterans Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"DOI":"10.1038\/s44259-025-00143-x","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:11Z","timestamp":1754337791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Parkinson\u2019s drug benztropine possesses histamine receptor 1-dependent host-directed antimicrobial activity against Mycobacterium tuberculosis"],"prefix":"10.1038","volume":"3","author":[{"given":"Henok A.","family":"Sahile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Christofferson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan A.","family":"Alford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Rens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasti","family":"Haghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E. W.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossef","family":"Av-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"143_CR1","unstructured":"WHO. Global Tuberculosis Report https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024 (2024)."},{"key":"143_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107138","volume":"63","author":"T Shapira","year":"2024","unstructured":"Shapira, T., Christofferson, M. & Av-Gay, Y. The antimicrobial activity of innate host-directed therapies: a systematic review. Int J. Antimicrob. Agents 63, 107138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107138 (2024).","journal-title":"Int J. Antimicrob. Agents"},{"key":"143_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12951","volume":"301","author":"G Kilin\u00e7","year":"2021","unstructured":"Kilin\u00e7, G., Saris, A., Ottenhoff, T. H. M. & Haks, M. C. Host-directed therapy to combat mycobacterial infections. Immunol. Rev. 301, 62\u201383, https:\/\/doi.org\/10.1111\/imr.12951 (2021).","journal-title":"Immunol. Rev."},{"key":"143_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","volume":"13","author":"C Young","year":"2020","unstructured":"Young, C., Walzl, G. & Du Plessis, N. Therapeutic host-directed strategies to improve outcome in tuberculosis. Mucosal Immunol. 13, 190\u2013204, https:\/\/doi.org\/10.1038\/s41385-019-0226-5 (2020).","journal-title":"Mucosal Immunol."},{"key":"143_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.chom.2018.08.001","volume":"24","author":"SB Cohen","year":"2018","unstructured":"Cohen, S. B. et al. Alveolar macrophages provide an early Mycobacterium tuberculosis niche and initiate dissemination. Cell Host Microbe 24, 439\u2013446.e4, https:\/\/doi.org\/10.1016\/j.chom.2018.08.001 (2018).","journal-title":"Cell Host Microbe"},{"key":"143_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/cid\/civ631","volume":"61","author":"A Zumla","year":"2015","unstructured":"Zumla, A. et al. Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the pasteur-bechamp debates. Clin. Infect. Dis. 61, 1432\u20131438, https:\/\/doi.org\/10.1093\/cid\/civ631 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"143_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660916","volume":"12","author":"S Krug","year":"2021","unstructured":"Krug, S., Parveen, S. & Bishai, W. R. Host-directed therapies: modulating inflammation to treat tuberculosis. Front. Immunol. 12, 660916. https:\/\/doi.org\/10.3389\/fimmu.2021.660916 (2021).","journal-title":"Front. Immunol."},{"key":"143_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fimmu.2016.00238","volume":"7","author":"S Subbian","year":"2016","unstructured":"Subbian, S. et al. Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis. Front. Immunol. 7, 238, https:\/\/doi.org\/10.3389\/fimmu.2016.00238 (2016).","journal-title":"Front. Immunol."},{"key":"143_CR9","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.3390\/ijms20122868","volume":"20","author":"E Torfs","year":"2019","unstructured":"Torfs, E., Piller, T., Cos, P. & Cappoen, D. Opportunities for overcoming Mycobacterium tuberculosis drug resistance: emerging mycobacterial targets and host-directed therapy. Int. J. Mol. Sci. 20, 2868, https:\/\/doi.org\/10.3390\/ijms20122868 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"143_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18699-9","volume":"11","author":"R Colangeli","year":"2020","unstructured":"Colangeli, R. et al. Mycobacterium tuberculosis progresses through two phases of latent infection in humans. Nat. Commun. 11, 4870. https:\/\/doi.org\/10.1038\/s41467-020-18699-9 (2020).","journal-title":"Nat. Commun."},{"key":"143_CR11","doi-asserted-by":"publisher","first-page":"m216","DOI":"10.1136\/bmj.m216","volume":"368","author":"A Lee","year":"2020","unstructured":"Lee, A., Xie, Y. L., Barry, C. E. & Chen, R. Y. Current and future treatments for tuberculosis. BMJ 368, m216, https:\/\/doi.org\/10.1136\/bmj.m216 (2020).","journal-title":"BMJ"},{"key":"143_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/infdis\/jiz517","volume":"221","author":"NK Dutta","year":"2020","unstructured":"Dutta, N. K. et al. Adjunctive host-directed therapy with statins improves tuberculosis-related outcomes in mice. J. Infect. Dis. 221, 1079\u20131087, https:\/\/doi.org\/10.1093\/infdis\/jiz517 (2020).","journal-title":"J. Infect. Dis."},{"key":"143_CR13","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.ijid.2019.01.039","volume":"80S","author":"M Rao","year":"2019","unstructured":"Rao, M. et al. Improving treatment outcomes for MDR-TB\u2014novel host-directed therapies and personalised medicine of the future. Int. J. Infect. Dis. 80S, S62\u2013S67, https:\/\/doi.org\/10.1016\/j.ijid.2019.01.039 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"143_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3389\/fmicb.2020.00435","volume":"11","author":"N Naicker","year":"2020","unstructured":"Naicker, N., Sigal, A. & Naidoo, K. Metformin as host-directed therapy for TB treatment: scoping review. Front. Microbiol. 11, 435, https:\/\/doi.org\/10.3389\/fmicb.2020.00435 (2020).","journal-title":"Front. Microbiol."},{"key":"143_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110555","volume":"27","author":"S Pe\u00f1a-D\u00edaz","year":"2024","unstructured":"Pe\u00f1a-D\u00edaz, S. et al. Glycogen synthase kinase 3 inhibition controls Mycobacterium tuberculosis infection. iScience 27, 110555. https:\/\/doi.org\/10.1016\/j.isci.2024.110555 (2024).","journal-title":"iScience"},{"key":"143_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/antibiotics9090550","volume":"9","author":"\u00c1 Mourenza","year":"2020","unstructured":"Mourenza, \u00c1, Gil, J. A., Mateos, L. M. & Letek, M. Novel treatments against Mycobacterium tuberculosis based on drug repurposing. Antibiotics 9, 550, https:\/\/doi.org\/10.3390\/antibiotics9090550 (2020).","journal-title":"Antibiotics"},{"key":"143_CR17","doi-asserted-by":"publisher","unstructured":"Sheerin, D., Abhimanyu, A., Wang, X., Johnson, W. E. & Coussens, A. Immunopathogenic overlap and shared therapeutic targets for Covid-19 and tuberculosis predicted from transcriptomic meta-analysis. SSRN Electron. J. https:\/\/doi.org\/10.2139\/ssrn.3815987 (2021).","DOI":"10.2139\/ssrn.3815987"},{"key":"143_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104464","volume":"25","author":"Sheerin","year":"2022","unstructured":"Sheerin et al. Immunopathogenic overlap between COVID-19 and tuberculosis identified from transcriptomic meta-analysis and human macrophage infection. iScience 25, 104464. https:\/\/doi.org\/10.1016\/j.isci.2022.104464 (2022).","journal-title":"iScience"},{"key":"143_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254206","volume":"14","author":"P Booysen","year":"2023","unstructured":"Booysen, P. et al. Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis. Front. Immunol. 14, 1254206. https:\/\/doi.org\/10.3389\/fimmu.2023.1254206 (2023).","journal-title":"Front. Immunol."},{"key":"143_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848373","volume":"13","author":"BB Mishra","year":"2022","unstructured":"Mishra, B. B., Essafi, M., Singh, R., Gupta, S. & Parihar, S. P. Editorial: repurposed drugs as immune-modulators to combat infectious diseases. Front. Immunol. 13, 848373. https:\/\/doi.org\/10.3389\/fimmu.2022.848373 (2022).","journal-title":"Front. Immunol."},{"key":"143_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760210207","volume":"116","author":"R Almeida-Paes","year":"2021","unstructured":"Almeida-Paes, R. et al. Medicines for malaria venture COVID box: a source for repurposing drugs with antifungal activity against human pathogenic fungi. Mem. Inst. Oswaldo Cruz 116, e210207. https:\/\/doi.org\/10.1590\/0074-02760210207 (2021).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"143_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.553962","volume":"11","author":"T Shapira","year":"2020","unstructured":"Shapira, T. et al. High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against Mycobacterium tuberculosis. Front. Microbiol. 11, 553962. https:\/\/doi.org\/10.3389\/fmicb.2020.553962 (2020).","journal-title":"Front. Microbiol."},{"key":"143_CR23","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1021\/acsomega.9b04173","volume":"5","author":"HA Sahile","year":"2020","unstructured":"Sahile, H. A., Rens, C., Shapira, T., Andersen, R. J. & Av-Gay, Y. DMN-Tre labeling for detection and high-content screening of compounds against intracellular mycobacteria. ACS Omega 5, 3661\u20133669, https:\/\/doi.org\/10.1021\/acsomega.9b04173 (2020).","journal-title":"ACS Omega"},{"key":"143_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly, B. S. & Lang, A. E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670\u20131683, https:\/\/doi.org\/10.1001\/jama.2014.3654 (2014).","journal-title":"JAMA"},{"key":"143_CR25","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0026-895X(25)12922-2","volume":"40","author":"Y Wang","year":"1991","unstructured":"Wang, Y. & Rosenberg, R. L. Ethaverine, a derivative of papaverine, inhibits cardiac L-type calcium channels. Mol. Pharm. 40, 750\u2013755 (1991).","journal-title":"Mol. Pharm."},{"key":"143_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0014-2999(02)01993-3","volume":"449","author":"Z T\u00f6m\u00f6sk\u00f6zi","year":"2002","unstructured":"T\u00f6m\u00f6sk\u00f6zi, Z., Finance, O. & Ar\u00e1nyi, P. Drotaverine interacts with the L-type Ca2+ channel in pregnant rat uterine membranes. Eur. J. Pharm. 449, 55\u201360, https:\/\/doi.org\/10.1016\/S0014-2999(02)01993-3 (2002).","journal-title":"Eur. J. Pharm."},{"key":"143_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102129","volume":"43","author":"A Muehler","year":"2020","unstructured":"Muehler, A., Peelen, E., Kohlhof, H., Gr\u00f6ppel, M. & Vitt, D. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 43, 102129. https:\/\/doi.org\/10.1016\/j.msard.2020.102129 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"143_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/15257770.2018.1508692","volume":"37","author":"GJ Peters","year":"2018","unstructured":"Peters, G. J. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor. Nucleosides Nucleotides Nucleic Acids 37, 666\u2013678, https:\/\/doi.org\/10.1080\/15257770.2018.1508692 (2018).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"143_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijantimicag.2014.11.017","volume":"45","author":"X Gonzalo","year":"2015","unstructured":"Gonzalo, X., Casali, N., Broda, A., Pardieu, C. & Drobniewski, F. Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis. Int J. Antimicrob. Agents 45, 406\u2013412, https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.11.017 (2015).","journal-title":"Int J. Antimicrob. Agents"},{"key":"143_CR30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S1473-3099(19)30418-9","volume":"19","author":"JD Stanaway","year":"2019","unstructured":"Stanaway, J. D. et al. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect. Dis. 19, 1312\u20131324, https:\/\/doi.org\/10.1016\/S1473-3099(19)30418-9 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"143_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14787210.2024.2368989","volume":"22","author":"Y Amir","year":"2024","unstructured":"Amir, Y. et al. The prevalence of antimicrobial drug resistance of non-typhoidal Salmonella in human infections in sub-Saharan Africa: a systematic review and meta-analysis. Expert Rev. Anti Infect. Ther.22, 761\u2013774, https:\/\/doi.org\/10.1080\/14787210.2024.2368989 (2024).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"143_CR32","first-page":"39","volume":"2","author":"DR Brocks","year":"1999","unstructured":"Brocks, D. R. Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharm. Sci. 2, 39\u201346 (1999).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"143_CR33","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1016\/j.bmc.2006.01.017","volume":"14","author":"SS Kulkarni","year":"2006","unstructured":"Kulkarni, S. S., Kopajtic, T. A., Katz, J. L. & Newman, A. H. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H1 receptors. Bioorg. Med. Chem. 14, 3625\u20133634, https:\/\/doi.org\/10.1016\/j.bmc.2006.01.017 (2006).","journal-title":"Bioorg. Med. Chem."},{"key":"143_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02004-22","volume":"13","author":"S Mo","year":"2022","unstructured":"Mo, S. et al. Mycobacterium tuberculosis utilizes host histamine receptor H1 to modulate reactive oxygen species production and phagosome maturation via the p38MAPK-NOX2 axis. mBio 13, e0200422. https:\/\/doi.org\/10.1128\/mbio.02004-22 (2022).","journal-title":"mBio"},{"key":"143_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12647","volume":"502","author":"VA Deshmukh","year":"2013","unstructured":"Deshmukh, V. A. et al. A regenerative approach to the treatment of multiple sclerosis. Nature 502, 327\u2013332, https:\/\/doi.org\/10.1038\/nature12647 (2013).","journal-title":"Nature"},{"key":"143_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/cancers12020523","volume":"12","author":"C Sogawa","year":"2020","unstructured":"Sogawa, C. et al. Antiparkinson drug benztropine suppresses tumor growth, circulating tumor cells, and metastasis by acting on SLC6A3\/dat and reducing STAT3. Cancers12, 523, https:\/\/doi.org\/10.3390\/cancers12020523 (2020).","journal-title":"Cancers"},{"key":"143_CR37","doi-asserted-by":"crossref","unstructured":"Kapellos, T. S. et al. A novel real time imaging platform to quantify macrophage phagocytosis. Biochem. Pharmacol. 116, 107\u2013119 (2016).","DOI":"10.1016\/j.bcp.2016.07.011"},{"key":"143_CR38","doi-asserted-by":"crossref","unstructured":"Vilch\u00e8ze, C. et al. Rational design of biosafety level 2-approved, multidrug-resistant strains of Mycobacterium tuberculosis through nutrient auxotrophy. mBio 9, e00938-18 (2018).","DOI":"10.1128\/mBio.00938-18"},{"key":"143_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00281-015-0538-9","volume":"38","author":"I Kramnik","year":"2016","unstructured":"Kramnik, I. & Beamer, G. Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. Semin Immunopathol. 38, 221\u2013237, https:\/\/doi.org\/10.1007\/s00281-015-0538-9 (2016).","journal-title":"Semin Immunopathol."},{"key":"143_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00140-17","volume":"8","author":"D Pletzer","year":"2017","unstructured":"Pletzer, D., Mansour, S. C., Wuerth, K., Rahanjam, N. & Hancock, R. E. W. New mouse model for chronic infections by gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions. mBio 8, e00140-17. https:\/\/doi.org\/10.1128\/mBio.00140-17 (2017).","journal-title":"mBio"},{"key":"143_CR41","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature02326","volume":"427","author":"MT Mira","year":"2004","unstructured":"Mira, M. T. et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427, 636\u2013640, https:\/\/doi.org\/10.1038\/nature02326 (2004).","journal-title":"Nature"},{"key":"143_CR42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00439-019-02087-5","volume":"139","author":"VM Fava","year":"2020","unstructured":"Fava, V. M., Dallmann-Sauer, M. & Schurr, E. Genetics of leprosy: today and beyond. Hum. Genet. 139, 835\u2013846, https:\/\/doi.org\/10.1007\/s00439-019-02087-5 (2020).","journal-title":"Hum. Genet."},{"key":"143_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798694","volume":"37","author":"A H\u00e4rtlova","year":"2018","unstructured":"H\u00e4rtlova, A. et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. EMBO J. 37, e98694. https:\/\/doi.org\/10.15252\/embj.201798694 (2018).","journal-title":"EMBO J."},{"key":"143_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fcimb.2019.00138","volume":"9","author":"KL Patrick","year":"2019","unstructured":"Patrick, K. L., Bell, S. L., Weindel, C. G. & Watson, R. O. Exploring the \u201cmultiple-hit hypothesis\u201d of neurodegenerative disease: bacterial infection comes up to bat. Front. Cell Infect. Microbiol. 9, 138, https:\/\/doi.org\/10.3389\/fcimb.2019.00138 (2019).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"143_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/01.jom.0000204114.01893.3e","volume":"48","author":"YM Jiang","year":"2006","unstructured":"Jiang, Y. M. et al. Effective treatment of manganese-induced occupational parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J. Occup. Environ. Med. 48, 644\u2013649, https:\/\/doi.org\/10.1097\/01.jom.0000204114.01893.3e (2006).","journal-title":"J. Occup. Environ. Med."},{"key":"143_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","volume":"32","author":"A Maitra","year":"2015","unstructured":"Maitra, A. et al. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis. Int. J. Infect. Dis. 32, 50\u201355, https:\/\/doi.org\/10.1016\/j.ijid.2014.12.031 (2015).","journal-title":"Int. J. Infect. Dis."},{"key":"143_CR47","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1128\/IAI.01497-08","volume":"77","author":"D Carlos","year":"2009","unstructured":"Carlos, D. et al. Histamine plays an essential regulatory role in lung inflammation and protective immunity in the acute phase of Mycobacterium tuberculosis infection. Infect. Immun. 77, 5359\u20135368, https:\/\/doi.org\/10.1128\/IAI.01497-08 (2009).","journal-title":"Infect. Immun."},{"key":"143_CR48","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1021\/jm970525a","volume":"40","author":"GE Agoston","year":"1997","unstructured":"Agoston, G. E. Novel N-substituted 3\u03b1-[bis(4\u2019-fluorophenyl)methoxy]tropane analogues: selective ligands for thedopamine transporter. J. Med. Chem 40, 4329\u20134339, https:\/\/doi.org\/10.1021\/jm970525a (1997).","journal-title":"J. Med. Chem"},{"key":"143_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1939-4551-1-9-145","volume":"1","author":"FER Simon","year":"2008","unstructured":"Simon, F. E. R. & Simons, K. J. H1 antihistamines: current status and future directions. World Allergy Organ J. 1, 145\u2013155, https:\/\/doi.org\/10.1186\/1939-4551-1-9-145 (2008).","journal-title":"World Allergy Organ J."},{"key":"143_CR50","doi-asserted-by":"publisher","first-page":"263ra159","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"A Singhal","year":"2014","unstructured":"Singhal, A. et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159, https:\/\/doi.org\/10.1126\/scitranslmed.3009885 (2014).","journal-title":"Sci. Transl. Med."},{"key":"143_CR51","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"SP Parihar","year":"2014","unstructured":"Parihar, S. P. et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 209, 754\u2013763, https:\/\/doi.org\/10.1093\/infdis\/jit550 (2014).","journal-title":"J. Infect. Dis."},{"key":"143_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"RJ Napier","year":"2011","unstructured":"Napier, R. J. et al. Imatinib-Sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475\u2013485, https:\/\/doi.org\/10.1016\/j.chom.2011.09.010 (2011).","journal-title":"Cell Host Microbe"},{"key":"143_CR53","doi-asserted-by":"publisher","first-page":"1293304","DOI":"10.4049\/jimmunol.1500931","volume":"196","author":"AE Reeme","year":"2016","unstructured":"Reeme, A. E. & Robinson, R. T. Dietary vitamin D3 suppresses pulmonary immunopathology associated with late-stage tuberculosis in C3HeB\/FeJ mice. J. Immunol. 196, 1293304, https:\/\/doi.org\/10.4049\/jimmunol.1500931 (2016).","journal-title":"J. Immunol."},{"key":"143_CR54","unstructured":"Cayman Chemical. Safety Data Sheet acc. to OSHA HCShttps:\/\/cdn.caymanchem.com\/cdn\/msds\/33474m.pdf (2023)."},{"key":"143_CR55","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00228-001-0405-6","volume":"57","author":"BG Reigner","year":"2002","unstructured":"Reigner, B. G. & Blesch, K. Estimating the starting dose for entry into humans: principles and practice. Eur. J. Clin. Pharm. 57, 835\u2013845, https:\/\/doi.org\/10.1007\/s00228-001-0405-6 (2002).","journal-title":"Eur. J. Clin. Pharm."},{"key":"143_CR56","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1099\/00221287-148-10-3007","volume":"148","author":"S Bardarov","year":"2002","unstructured":"Bardarov, S. et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology148, 3007\u20133017, https:\/\/doi.org\/10.1099\/00221287-148-10-3007 (2002).","journal-title":"Microbiology"},{"key":"143_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102222","volume":"135","author":"S Kalsum","year":"2022","unstructured":"Kalsum, S. et al. A high content screening assay for discovery of antimycobacterial compounds based on primary human macrophages infected with virulent Mycobacterium tuberculosis. Tuberculosis135, 102222. https:\/\/doi.org\/10.1016\/j.tube.2022.102222 (2022).","journal-title":"Tuberculosis"},{"key":"143_CR58","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1128\/JB.185.16.4973-4982.2003","volume":"185","author":"J Bjarnason","year":"2003","unstructured":"Bjarnason, J., Southward, C. M. & Surette, M. G. Genomic profiling of iron-responsive genes in Salmonella enterica serovar Typhimurium by high-throughput screening of a random promoter library. J. Bacteriol. 185, 4973\u20134982, https:\/\/doi.org\/10.1128\/JB.185.16.4973-4982.2003 (2003).","journal-title":"J. Bacteriol."},{"key":"143_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-0716-1971-1_7","volume":"2427","author":"L Rankine-Wilson","year":"2022","unstructured":"Rankine-Wilson, L., Rens, C., Sahile, H. A. & Av-Gay, Y. Mycobacterium tuberculosis Infection of THP-1 cells: a model for high content analysis of intracellular growth and drug susceptibility. Methods Mol. Biol. 2427, 73\u201382, https:\/\/doi.org\/10.1007\/978-1-0716-1971-1_7 (2022).","journal-title":"Methods Mol. Biol."},{"key":"143_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2020.101977","volume":"124","author":"B Andersson","year":"2020","unstructured":"Andersson, B., Nordvall, M. J., Welin, A., Lerm, M. & Sch\u00f6n, T. A novel mycobacterial growth inhibition assay employing live-cell imaging of virulent M. tuberculosis and monitoring of host cell viability. Tuberculosis124, 101977. https:\/\/doi.org\/10.1016\/j.tube.2020.101977 (2020).","journal-title":"Tuberculosis"},{"key":"143_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24127-3","volume":"12","author":"P Santucci","year":"2021","unstructured":"Santucci, P. et al. Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. Nat. Commun. 12, 3816. https:\/\/doi.org\/10.1038\/s41467-021-24127-3 (2021).","journal-title":"Nat. Commun."},{"key":"143_CR62","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao, X., Huang, X., Zhou, Z. & Lin, X. An improvement of the 2\u02c6(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat. Bioinforma. Biomath. 3, 71\u201385 (2013).","journal-title":"Biostat. Bioinforma. Biomath."},{"key":"143_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/cpmb.100","volume":"128","author":"CJ Giuliano","year":"2019","unstructured":"Giuliano, C. J., Lin, A., Girish, V. & Sheltzer, J. M. Generating single cell\u2013derived knockout clones in mammalian cells with CRISPR\/Cas9. Curr. Protoc. Mol. Biol. 128, e100. https:\/\/doi.org\/10.1002\/cpmb.100 (2019).","journal-title":"Curr. Protoc. Mol. Biol."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00143-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00143-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00143-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:03:45Z","timestamp":1754420625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00143-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["143"],"URL":"https:\/\/doi.org\/10.1038\/s44259-025-00143-x","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The mouse Mtb and STm infection trials were conducted in accordance with Canadian Council on Animal Care (CCAC) guidelines and approved by the University of Saskatchewan Animal Research Ethics Board (Protocol #20230084) and the University of British Columbia Animal Care Committee (Protocol A23-0030-A002), respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"70"}}